Part D not immune to fraud

Executive Summary

Identifying fraud in the Medicare prescription drug program may be difficult relative to other government programs due to a lack of transparency in the market, witnesses at a House Committee on Oversight and Government Reform hearing on pharmaceutical waste, fraud and abuse suggest. The Feb. 9 hearing also addresses fraud and abuse related to Medicaid pricing and the 340B program. Waxman indicates that issues such as the susceptibility of Part D to fraud and the limitations of enforcement efforts to effectively litigate violations will be an integral part of the committee's investigative priorities for the next two years...